A Single-dose, Randomised, Crossover, Placebo-controlled Study Assessing Two Fixed-dose Combinations of Inhaled Long-acting Beta-agonist and Corticosteroid
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Almirall, S.A.
This is a Phase 1, randomised, double-blind, double-dummy, cross-over trial to assess the bronchodilation effect of a single dose of LAS40468 and a single dose of salmeterol/fluticasone propionate (Seretide®) administered to adult patients with stable asthma.
The study will consist of a screening visit and treatment periods of approximately 13 hours separated by washout periods of 7 to 14 days from the time of Investigational Medicinal product (IMP) administration.
Age
18–60
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult males and non-pregnant, non-lactating females aged between 18 and 60 years (both inclusive)
Patients with a confirmed 6-months' history of asthma at the time of enrolment into the trial
Patients treated with short-acting beta-agonists or inhaled corticosteroids at a stable dose and regimen (up to the equivalent of 1600 μg/day of beclometasone dipropionate) for at least 4 weeks prior to screening
Patients whose (pre-salbutamol) forced expiratory volume in 1 second (FEV1) at screening is \>60% of the predicted normal value after a washout of at least 6 hours for short-acting beta-agonists and 48 hours for long-acting beta-agonists, if applicable
Patients with a FEV1 absolute increase of at least 250 mL over baseline value after inhalation of 4 puffs of 100 μg of salbutamol in one of two pulmonary function tests performed within 10-15 min
You may not be if
Patients with clinically significant respiratory or pulmonary diseases other than asthma or history of thoracic surgery
Patients with a Body Mass Index (BMI) \< 18 or \> 40kg/m2 (both inclusive)